[en] BACKGROUND: Some patients with Cushing's syndrome have nodular adrenal hyperplasia. In most the disease is corticotropin-dependent, but in others it is corticotropin-independent. The cause of the adrenal hyperplasia in the latter patients is not known. METHODS: We studied a 49-year-old woman with Cushing's syndrome and nodular adrenal hyperplasia in whom food stimulated cortisol secretion. Plasma cortisol concentrations were measured in response to the ingestion of mixed meals, glucose, protein, and fat and after the administration of various gastrointestinal and other types of hormones. We also studied the ability of the long-acting somatostatin analogue octreotide to prevent the food-induced increase in plasma cortisol concentrations and to ameliorate the clinical manifestations of Cushing's syndrome in this patient. RESULTS: The patient's fasting plasma cortisol concentrations were subnormal, ranging from 3.0 to 7.5 micrograms per deciliter (83 to 207 nmol per liter), and they increased to as high as 16.5 micrograms per deciliter (455 nmol per liter) after a mixed meal. Her urinary cortisol excretion ranged from 164 to 250 micrograms per day (453 to 690 nmol per day) and could not be suppressed by a large dose of dexamethasone. Plasma corticotropin concentrations were virtually undetectable at all times. The ingestion of glucose, protein, and fat increased plasma cortisol concentrations to 3.6, 2.2, and 4 times the base-line value, respectively; the meal-induced and glucose-induced increases were inhibited by octreotide. The infusion of gastric inhibitory polypeptide (GIP) increased the patient's plasma cortisol concentration to 3.7 times the base-line value, but had no effect in normal subjects. The patient's fasting plasma GIP concentrations were normal both before and after a meal, and there was a close correlation between her plasma cortisol and GIP concentrations. Treatment with octreotide decreased urinary cortisol excretion and ameliorated the clinical manifestations of Cushing's syndrome. CONCLUSIONS: The development of aberrant adrenal sensitivity to GIP can result in food-dependent adrenal hyperplasia and therefore in Cushing's syndrome.
Rees LH, Landon J. Biochemical abnormalities in some human neoplasms. 5. Inappropriate biosynthesis of hormones by tumours. In: Symington T, Carter RL, eds. Scientific foundations of oncology. London: William Heinemann Medical Books, 1976:112.
Schorr I, Rathnam P, Saxena BB, Ney RL. Multiple specific hormone receptors in the adenylate cyclase of an adrenocortical carcinoma. J Biol Chem 1971; 246: 5806–11.
Katz MS, Kelly TM, Dax EM, Pineyro MA, Panilla JS, Gregerman RI. Ectopic β-adrenergic receptors coupled to adenylate cyclase in human adrenocortical carcinomas. J Clin Endocrinol Metab 1985; 60: 900–9.
Hamet P, Larochelle P, Franks DJ, Cartier P, Bolte E. Cushing syndrome with food-dependent periodic hormonogenesis. Clin Invest Med 1987; 10: 530–3.
Larsen JL, Cathey WJ, Odell WD. Primary adrenocortical nodular dysplasia, a distinct subtype of Cushing's syndrome: case report and review of the literature. Am J Med 1986; 80: 976–84.
Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VLW.The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64: 270–83.
Young WF Jr, Carney JA, Musa BU, Wulffraat NM, Lens JW, Drexhage HA. Familial Cushing's syndrome due to primary pigmented nodular adrenocortical disease: reinvestigation 50 years later. N Engl J Med 1989; 321: 1659–64.
Teding van Berkhout F, Croughs RJM, Wulffraat NM, Drexhage HA. Familial Cushing's syndrome due to nodular adrenocortical dysplasia is an inherited disease of immunological origin. Clin Endocrinol (Oxf) 1989; 31: 185–91.
Wulffraat NM, Drexhage HA, Wiersinga WM, van der Gaag RD, Jeucken P, Mol JA. Immunoglobulins of patients with Cushing's syndrome due to pigmented adrenocortical micronodular dysplasia stimulate in vitro steroidogenesis. J Clin Endocrinol Metab 1988; 66: 301–7.
Lacroix A, Bolté E, Poitras P, et al. Gastric inhibitory polypeptide-dependent macronodular adrenal hyperplasia: a new etiology of Cushing's syndrome. In: Program and abstracts of the 73rd Annual Meeting of the Endocrine Society, Washington, D.C., June 19–22, 1991. Bethesda, Md.: Endocrine Society, 1991:91. abstract.
Lacroix A, Boité E, Tremblay J, et al. Gastric inhibitory polypeptide—dependent cortisol hypersecretion — a new cause of Cushing's syndrome. N Engl J Med 1992; 327: 974–80.
O'Donnell LJD, Farthing MJG. Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases. Gut 1989; 30: 1165–72.
Miazza B, Palma R, Lachance JR, Chayvialle JA, Jonard PP, Modigliani R. Jejunal secretory effect of intraduodenal food in humans: a comparison of mixed nutrients, proteins, lipids, and carbohydrates. Gastroenterology 1985; 88: 1215–22.
Penhoat A, Sanchez P, Jaillard C, Langlois D, Bégeot M, Saez JM. Human proopiomelanocortin-(79–96), a proposed cortical androgen-stimulating hormone, does not affect steroidogenesis in cultured human adult adrenal cells. J Clin Endocrinol Metab 1991; 72: 23–6.
Woltering EA, Mozell EJ, O'Dorisio TM, Fletcher WS, Howe B. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors. Surg Gynecol Obstet 1988; 167: 453–62.
Jaffe BM. Hormones of the gastrointestinal tract. In: DeGroot LJ, Cahill GF Jr, Odell WD, et al., eds. Endocrinology. Vol. 3. New York: Grune & Stratton, 1979:1669–98.
Cataland S, Crockett SE, Brown JC, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 1974; 39: 223–8.
Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826–8.
Weitzman ED, Fukushima DK, Nogeire C, Roffwarg H, Gallagher TF, Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33: 14–22.
de Lacerda L, Kowarski A, Migeon CJ. Integrated concentrations and diurnal variation of plasma cortisol. J Clin Endocrinol Metab 1973; 36: 227–38.
Vagnucci AH, McDonald RH Jr, Drash AL, Wong AKC. Intradiem changes of plasma aldosterone, cortisol, corticosterone and growth hormone in sodium restriction. J Clin Endocrinol Metab 1974; 38: 761–76.
Brandenburger G, Follenius M, Siméoni M. Variations diurnes de la cortisolémie, de la glycémie et du cortisol libre urinaire chez l'homme au repos. J Physiol (Paris) 1973; 66: 271–82.
Quigley ME, Yen SSC. A mid-day surge in cortisol levels. J Clin Endocrinol Metab 1979; 49: 945–7.
Follenius M, Brandenberger G, Hietter B, Siméoni M, Reinhardt B. Diurnal cortisol peaks and their relationships to meals. J Clin Endocrinol Metab 1982; 55: 757–61.
Ishizuka B, Quigley ME, Yen SSC. Pituitary hormone release in response to food ingestion: evidence for neuroendocrine signals from gut and brain. J Clin Endocrinol Metab 1983; 57: 1111–6.
Larochelle P, Du Souich P, Bolte E, Lelorier J, Goyer R. Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application. Clin Pharmacol Ther 1983; 33: 343–50.
Al-Damluji S, Iveson T, Thomas JM, Pendlebury DJ, Rees LH, Besser GM. Food-induced cortisol secretion is mediated by central alpha-1 adrenoreceptor modulation of pituitary ACTH secretion. Clin Endocrinol (Oxf) 1987; 26: 629–36.
Knigge U, Holst JJ, Knuhtsen S, Bach FW, Bang P. Corticotropin-releasing activity of gastrin-releasing peptide in normal men. J Clin Endocrinol Metab 1987; 65: 1291–5.
Ambrosi B, Bochicchio D, Sartorio A, Morabito F, Faglia G. Vasoactive intestinal polypeptide enhances ACTH levels in some patients with adrenocorticotropin-secreting pituitary adenomas. Acta Endocrinol (Copenh) 1987; 116: 216–20.